



The Risk Evaluation and Education for Alzheimer's Disease - The Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN) Study

Understanding how people respond to learning their risk of developing Alzheimer's disease (AD) dementia and amyloid PET scan results will help researchers and clinicians more effectively communicate with patients and research participants about AD dementia risk and the role of amyloid.

All participants will be followed for 6-7 months after learning their estimated risk of developing AD dementia by age 85.

Half of the participants will learn their amyloid scan result along with their risk estimate, and the other half will learn the scan result 7 months later. Participants are randomly assigned to one of these two groups.

REVEAL-SCAN is not a treatment study. You will not receive any medication in this study.

The decision to join the REVEAL-SCAN Study and learn the result of your amyloid PET scan is up to you.

What is REVEAL-SCAN?

REVEAL-SCAN is a multi-site study funded by the National Institutes of Health, with support from the Alzheimer's Association. The purpose of the study is to understand how people respond to learning their risk of developing Alzheimer's disease dementia.

Each participant in REVEAL-SCAN receives a personalized estimate of his or her risk of developing Alzheimer's disease dementia by the age of 85. This risk is based on current age, race, gender, and family history of Alzheimer's disease dementia.

Participants will have amyloid neuroimaging, also known as an amyloid brain scan, or an amyloid PET scan.

Who can participate?

- Healthy adults age 65 to 80 with no memory problems
- Must have a first-degree relative (parents or sibling) with a diagnosis of Alzheimer's disease dementia
- Must have a reliable study partner who can come to appointment
- Must meet research study criteria by answering screening questions

What does the study include?

- An in-person educational session
- A personalized risk assessment for Alzheimer's disease dementia
- A PET scan to learn if you have elevated amyloid in your brain
- Up to 7 study appointments and questionnaires spanning up to 9 months
- Measures of memory and thinking, mood, and health behaviors

Compensation

Participants will be compensated for their time and travel.

For more information, contact
Melissa Esparza at 215-662-6093 or
melissa.esparza@uphs.upenn.edu.

Penn Memory Center | Perelman Center for Advanced Medicine
3400 Civic Center Blvd., Philadelphia | www.pennmemorycenter.org